LianHuaQingwen: China Embassy flexes FDA approval of TCM drug for COVID cases

The Phillippine Food and Drug Administration has approved the sale of a traditional Chinese Medicine (TCM) drug for mild COVID-19 cases.

This as announced by the Chinese Embassy in the Philippines which called it as “an important progress in the entry of TCM products into the Philippine market.”

Lianhua Qingwen capsule was approved by FDA director Jesusa Joyce N. Cirunay on 7 August 2020 for sale in the Philippines up to 7 Feburary 2021.

The Chinese Embassy said the Lianhua Qingwen was an approved COVID19 treatment for mild and moderate cases in China and has so far been approved in Hong Kong and Macao SAR of China, Brazil, Indonesia,Canada, Mozambique, Romania, Thailand, Ecuador, Singapore and Laos PDR.

“It is our sincere hope that its entrance into the Philippine market will contribute to the fight against the spread of COVID-19 in this country and help the patients with mild and moderate symptoms recover,” the Chinese Embassy The TCM drug – which used Weeping Forsythia fruit; Japan Honeysuckle flower; Gypsum Fibrosum; Isatis root; Nakai Rizome and Frond bases – reportedly helps removes heat toxin invasion of the lungs including symptoms such as fever, aversion to cold, muscle soreness and runny nose.

The drug is manufactured by Shijiazhuang Yiling Pharmaceutical Co. Ltd. From Hebei province in China. The local distributor is Philippine Archipelago International Trading Corp. in Balintawak, Quezon City.

“The Embassy advises the consumers to purchase and consume authentic TCM produced by qualified pharmaceutical manufacturers, and hopes that TCM would play a bigger role to support the efforts of the Philippine government and its people to fight against COVID-19 until the final victory,” the Chinese Embassy said.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.